A Review of The Utility Values Used in Published Cost-Effectiveness Analyses of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy in Patients With Diabetic Nephropathy
Abstract
Authors
R. Paczkowski T. Kennedy-Martin S. Rayner